课题基金基金详情
中国人群CYP2C9新变异体的体外代谢功能及临床意义研究
结题报告
批准号:
31371280
项目类别:
面上项目
资助金额:
80.0 万元
负责人:
戴大鹏
依托单位:
学科分类:
C0604.表型、行为与疾病的遗传学基础
结题年份:
2017
批准年份:
2013
项目状态:
已结题
项目参与者:
杨丽萍、张亚同、李传保、耿培武、徐涛、罗俊、罗顺斌、贾娜、姜文亮
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
大约15%的临床药物经CYP2C9代谢,基因型的差异是造成部分患者用药剂量个体差异大的重要因素之一。最近我们对2127例汉族人群进行基因扫描,共发现21种新等位基因(*36-*56)。利用C0S-7细胞发现,17种变异体对非甾体抗炎药物双氯芬酸的代谢特性发生了明显改变。为明确新变异是否会影响CYP2C9酶对其他药物的代谢活性,本研究拟开展以下3个层次的系统研究:首先体外大量表达各变异体,利用昆虫微粒体系统研究其对10种以上临床常用药物及抑制剂的体外代谢活性,筛选药代特性发生明显改变的有效突变体;其次招募健康人群开展药理实验加以验证和分析;最后招募900例以上华法林(CYP2C9典型探针底物药)长期服药病人进行遗传学分析,寻找新突变的携带者并考察其与药物使用剂量间的关系。旨在系统阐明CYP2C9新变异体的主要药物代谢特性及临床意义,为有效指导临床用药,从真正意义上实现个体化用药提供理论依据。
英文摘要
About 15 percent of therapeutically important drugs are metabolized by cytochrome P450 2C9(CYP2C9).CYP2C9 exhibits marked interindividual variability in its expression and catalytic activity due to functionally significant genetic variations, which is the main reason for the diverse clicinal medicican dosages in some patients. Recently, we detected 22 novel non-synonymous mutations in CYP2C9 after a sytematic genetic screen in 2127 Chinese Han population, in which, 21 new muation types have been nominated as new alleles *36-*56 by the Human CYP Allele Nomenclature Committee. in vitro functional analysis revealed that 17 new alleles showed different catalyitic activity toward the non-steroidal anti-inflammatory drug diclofenac compared to which of wild type *1 in transfected COS-7 cells. To elucidate whether these novel muations could affect the biological function of CYP2C9 protein toward other cilinical drugs, here we plan to perform the following studies at three different levels: First, highly express all the acquired variants in insect cells and systemically assesse the in vitro catalytic character of each variant toward at least 10 CYP2C9 specific drug substrates and some inhibitor drugs. Second,perform the clinical pharmacological study in some representative allelic healthy carriers in order to investigate their demic effects in vivo. Third,perform the association study of CYP2C9 genetic polymorhism and the drug oral dose of 900 patients who use the anticoagulant drug wafarin, an typical CYP2C9 phenotyping probe substrate, for at least 1 month. Our systematic clinical and functional studys of these new CYP2C9 alleles will pave the theoretical foundation for the therapeutic recommendations and personalized medicine in the Chinese population.
本研究体外表达了全部21种新发现的CYP2C9突变体,系统分析了新突变体的体外药物代谢活性,发现绝大多数突变体的药物代谢活性均出现明显下降。在此基础之上,本研究还开展了24种CYP2C19及22种CYP2D6新突变体的体外表达和药代学活性分析,与CYP2C9类似,CYP2C19、CYP2D6新突变体的活性多数明显降低。人体药代动力学研究表明,CYP2C9新突变体携带者的药物代谢活性也出现了明显降低。临床大样本基因分型研究发现了3种新的CYP2C9突变类型,同时提出了适合中国汉族人群华法林使用剂量的预测模型。该研究从体外纯蛋白、体内人体药动学、临床常用代谢药物剂量预测等多个角度,系统分析了CYP2C9新发现突变体的生物学功能及临床意义,为临床个体化指导用药提供了最为直接的理论依据。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro
CYP2C9基因多态性对氟比洛芬体外代谢的影响
DOI:10.3109/03639045.2014.950274
发表时间:2015-07
期刊:Drug Development and Industrial Pharmacy
影响因子:3.4
作者:Wang Li;Bao Shi-Hui;Pan Pei-Pei;Xia Meng-Ming;Chen Meng-Chun;Liang Bing-Qing;Dai Da-Peng;Cai Jian-Ping;Hu Guo-Xin
通讯作者:Hu Guo-Xin
Effects of Cytochrome P450 2C9 Polymorphism on Bosentan Metabolism
细胞色素P450 2C9多态性对波生坦代谢的影响
DOI:10.1124/dmd.114.060244
发表时间:2014-11-01
期刊:DRUG METABOLISM AND DISPOSITION
影响因子:3.9
作者:Chen, Mengchun;Zhang, Youting;Hu, Guoxin
通讯作者:Hu, Guoxin
The role of CYP2C9 genetic polymorphisms in theoxidative metabolism of diclofenac in vitro
CYP2C9基因多态性在双氯芬酸体外氧化代谢中的作用
DOI:--
发表时间:2014
期刊:Pharmazie
影响因子:1.6
作者:Xia MM;Wang L;Pan PP;Wang HY;Chen MC;Chen Y;Dai DP;Cai JP;Hu GX
通讯作者:Hu GX
Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro
中国人群中发现的22个CYP2D6变异对托特罗定体外代谢的影响
DOI:10.1016/j.cbi.2017.01.003
发表时间:2017
期刊:Chemico-Biological Interactions
影响因子:5.1
作者:Wang Hao;Dai Da-Peng;Sun Peng;Xu Li-Ping;Liang Bing-Qing;Cai Jian-Ping;Hu Guo-Xin
通讯作者:Hu Guo-Xin
In Vitro Assessment of 36 CYP2C9 Allelic Isoforms Found in the Chinese Population on the Metabolism of Glimepiride
中国人群中发现的 36 个 CYP2C9 等位基因亚型对格列美脲代谢的体外评估
DOI:10.1111/bcpt.12159
发表时间:2014-04-01
期刊:BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
影响因子:3.1
作者:Dai, Da-Peng;Wang, Shuang-Hu;Cai, Jian-Ping
通讯作者:Cai, Jian-Ping
基于全基因组CRISPR/CAS9筛选技术鉴定RNA氧化修饰关键修复基因及其功能机制研究
  • 批准号:
    81971323
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2019
  • 负责人:
    戴大鹏
  • 依托单位:
国内基金
海外基金